Retinal Pharmacotherapeutics

Editor(s): Nguyen, Q.D. (Omaha, NE)
Rodrigues, E.B. (São Paulo)
Farah, M.E. (São Paulo)
Mieler, W.F. (Chicago, IL)
Do, D.V. (Omaha, NE)

Retinal Diseases Amenable to Pharmacotherapy

Ocular Infection: Endophthalmitis

Schwartz S.G.a · Flynn Jr H.W.a · Das T.c · Mieler W.F.b

Author affiliations

aDepartment of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL, and bDepartment of Ophthalmology, University of Illinois College of Medicine at Chicago, Chicago, IL, USA; cDepartment of Ophthalmology, LV Prasad Eye Institute, Hyderabad, India

Related Articles for ""
Nguyen QD, Rodrigues EB, Farah ME, Mieler WF, Do DV (eds): Retinal Pharmacotherapeutics. Dev Ophthalmol. Basel, Karger, 2016, vol 55, pp 176-188
https://doi.org/10.1159/000431195

Log in to MyKarger to check if you already have access to this content.




Forgot your password
Sign up to MyKarger

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more
CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!


If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00

Select

Complete book

  • Immediate access to all parts of this book
  • Cover-to-cover formats may be available
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restriction for personal use
read more

Pricing depends on hard-cover price

Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Retinal Diseases Amenable to Pharmacotherapy

Published online: October 26, 2015
Cover Date: 2016

Number of Print Pages: 13
Number of Figures: 3
Number of Tables: 6

ISBN: 978-3-318-05564-1 (Print)
eISBN: 978-3-318-05565-8 (Online)

Abstract

Endophthalmitis is characterized by marked inflammation of intraocular fluids and tissues. Infective endophthalmitis may be categorized by the cause of the infection, which helps predict the underlying etiology and most likely causative organisms. The major category remains acute-onset postoperative endophthalmitis. Infective endophthalmitis is a clinical diagnosis but is confirmed by evaluation of intraocular fluid specimens. The Endophthalmitis Vitrectomy Study offered important guidelines for the initial management of endophthalmitis, and these guidelines remain relevant to this day. Prompt initiation of empiric broad-spectrum antimicrobial therapy is important in achieving best outcomes.

© 2016 S. Karger AG, Basel



Related Articles:

References

  1. Doft B: Endophthalmitis Management. Focal Points: Modules for Clinicians. San Francisco, American Academy of Ophthalmology, 1997.
  2. Shirodkar AR, Pathengay A, Flynn HW Jr, et al: Delayed- versus acute-onset endophthalmitis after cataract surgery. Am J Ophthalmol 2012;153:391-398.
  3. Jacobs DJ, Leng T, Flynn HW Jr, et al: Delayed-onset bleb-associated endophthalmitis: presentation and outcome by culture result. Clin Ophthalmol 2011;5:739-744.
  4. Henry CR, Flynn HW Jr, Miller D, et al: Delayed-onset endophthalmitis associated with corneal suture infections. J Ophthalmic Inflamm Infect 2013;3:51.
  5. Ahmed Y, Pathengay A, Flynn HW Jr, Isom R: Delayed-onset endophthalmitis associated with Ex-PRESS mini glaucoma shunt. Ophthalmic Surg Lasers Imaging 2012;43:e62-e63.
  6. Rosenberg KD, Flynn HW Jr, Alfonso EC, et al: Fusarium endophthalmitis following keratitis associated with contact lenses. Ophthalmic Surg Lasers Imaging 2006;37:310-313.
  7. Schwartz SG, Flynn HW, Scott IU: Endophthalmitis after intravitreal injections (review). Expert Opin Pharmacother 2009;10:2119-2126.
  8. Lundstrom M, Wejde G, Stenevi U, et al: Endophthalmitis after cataract surgery: a nationwide prospective study evaluating incidence in relation to incision type and location. Ophthalmology 2007;114:866-870.
  9. Patwardhan A, Rao GP, Saha K, et al: Incidence and outcomes evaluation of endophthalmitis management after phacoemulsification and 3-piece silicone intraocular lens implantation over 6 years in a single eye unit. J Cataract Refract Surg 2006;32:1018-1021.
  10. Kamalarajah S, Silvestri G, Sharma N, et al: Surveillance of endophthalmitis following cataract surgery in the UK. Eye (Lond) 2004;18:580-587.
  11. Miller JJ, Scott IU, Flynn HW Jr, et al: Acute-onset endophthalmitis after cataract surgery (2000-2004): incidence, clinical settings, and visual acuity outcomes after treatment. Am J Ophthalmol 2005;139:983-987.
  12. Das T, Hussain A, Naduvilath T, et al: Case control analyses of acute endophthalmitis after cataract surgery in South India associated with technique, patient care, and socioeconomic factors. J Ophthalmol 2012;2012:298459.
  13. Eifrig CWG, Flynn HW Jr, Scott IU, et al: Acute-onset postoperative endophthalmitis: review of incidence and visual outcomes (1995-2001). Ophthalmic Surg Lasers 2002;33:373-378.
  14. West ES, Behrens A, McDonnell PJ, et al: The incidence of endophthalmitis after cataract surgery among the U.S. Medicare population increased between 1994 and 2001. Ophthalmology 2005;112:1388-1394.
  15. Govetto A, Virgili G, Menchini F, Lanzetta P, Menchini U: A systematic review of endophthalmitis after microincisional versus 20-gauge vitrectomy. Ophthalmology 2013;120:2286-2291.
  16. Essex RW, Yi Q, Charles PG, et al: Post-traumatic endophthalmitis. Ophthalmology 2004;111:2015-2022.
  17. Gragoudas ES, Adamis AP, Cunningham ET Jr, et al: Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-2816.
  18. Heier JS, Antoszyk AN, Pavan PR, et al: Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. Ophthalmology 2006;133:633-642.
  19. Brown DM, Kaiser PK, Michels M, et al: Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-1444.
  20. Rosenfeld PR, Brown DM, Heier JS, et al: Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431.
  21. Heier JS, Brown DM, Chong V, et al: Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 2012;119:2537-2548.
  22. Comparison of Age-Related Macular Degeneration Treatment Trials (CATT) Research Group, Martin DF, Maguire MG, et al: Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012;119:1388-1398.
  23. Fung AE, Rosenfeld PJ, Reichel E: The international intravitreal bevacizumab safety survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 2006;90:1344-1349.
  24. Rasmussen A, Bloch SB, Fuchs J, et al: A 4-year longitudinal study of 555 patients treated with ranibizumab for neovascular age-related macular degeneration. Ophthalmology 2013;120:2630-2636.
  25. Gillies MC, Walton R, Simpson JM, et al: Prospective audit of exudative age-related macular degeneration: 12-month outcomes in treatment-naïve eyes. Invest Ophthalmol Vis Sci 2013;54:5754-5760.
  26. Englander M, Chen TC, Paschalis EI, et al: Intravitreal injections at the Massachusetts Eye and Ear Infirmary: analysis of treatment indications and postinjection endophthalmitis rates. Br J Ophthalmol 2013;97:460-465.
  27. Moshfeghi AA, Rosenfeld PJ, Flynn HW Jr, et al: Endophthalmitis after intravitreal vascular [corrected] endothelial growth factor antagonists: a six-year experience at a university referral center. Retina 2011;31:662-668.
  28. Fineman HS, Hsu J, Spirn MJ, Kaiser RS: Bimanual assisted eyelid retraction technique for intravitreal injections. Retina 2013;33:1968-1970.
  29. Shimada H, Hattori T, Mori R, et al: Minimizing the endophthalmitis rate following intravitreal injections using 0.25% povidone-iodine irrigation and surgical mask. Graefes Arch Clin Exp Ophthalmol 2013;251:1885-1890.
  30. Mithal K, Mathai A, Pathengay A, et al: Endophthalmitis following intravitreal anti-VEGF injections in ambulatory surgical centre facility: incidence, management and outcome. Br J Ophthalmol 2013;97:1609-1612.
  31. Westfall AC, Osborn A, Kuhl D, et al: Acute endophthalmitis incidence: intravitreal triamcinolone. Arch Ophthalmol 2005;123:1075-1077.
  32. Moshfeghi DM, Kaiser PK, Scott IU, et al: Acute endophthalmitis following intravitreal triamcinolone acetonide injection. Am J Ophthalmol 2003;136:791-796.
  33. Ciulla TA, Starr MB, Masket S: Bacterial endophthalmitis prophylaxis for cataract surgery: an evidence-based update. Ophthalmology 2002;109:13-26.
  34. Wallin T, Parker J, Jin Y, et al: Cohort study of 27 cases of endophthalmitis at a single institution. J Cataract Refract Surg 2005;31:735-741.
  35. Cao H, Zhang L, Li L, Lo S: Risk factors for acute endophthalmitis following cataract surgery: a systematic review and meta-analysis. PLoS One 2013;8:e71731.
  36. Lalwani GA, Flynn HW Jr, Scott IU, et al: Acute-onset endophthalmitis after clear corneal cataract surgery (1996-2005): clinical features, causative organisms, and visual acuity outcomes. Ophthalmology 2008;115:473-476.
  37. Barry P, Seal DV, Gettinby G, et al: ESCRS study of prophylaxis of postoperative endophthalmitis after cataract surgery: preliminary report of principal results from a European multicenter study. J Cataract Refract Surg 2006;32:407-410.
  38. Behndig A, Cochener B, Guell JL, et al: Endophthalmitis prophylaxis in cataract surgery: overview of current practice patterns in 9 European countries. J Cataract Refract Surg 2013;39:1421-1431.
  39. Gower EW, Lindsley K, Nanji AA, Leyngold I, McDonnell PJ: Perioperative antibiotics for prevention of acute endophthalmitis after cataract surgery. Cochrane Database Syst Rev 2013;7:CD006364.
  40. Ahmed Y, Schimel AM, Pathengay A, Colyer MH, Flynn HW Jr: Endophthalmitis following open-globe injuries. Eye (Lond) 2012;26:212-217.
  41. Parke DW 3rd, Pathengay A, Flynn HW Jr, Albini T, Schwartz SG: Risk factors for endophthalmitis and retinal detachment with retained intraocular foreign bodies. J Ophthalmol 2012;2012:758526.
  42. Schiedler V, Scott IU, Flynn HW Jr, et al: Culture-proven endogenous endophthalmitis: clinical features and visual acuity outcomes. Am J Ophthalmol 2004;137:725-731.
  43. Aziz HA, Berrocal AM, Sisk RA, et al: Intraocular infections in the neonatal intensive care unit. Clin Ophthalmol 2012;6:733-737.
  44. Henry CR, Flynn HW Jr, Miller D, Forster RK, Alfonso EC: Infectious keratitis progressing to endophthalmitis: a 15-year study of microbiology, associated factors, and clinical outcomes. Ophthalmology 2012;119:2443-2449.
  45. Sheyman AT, Cohen BZ, Friedman AH, Ackert JM: An outbreak of fungal endophthalmitis after intravitreal injection of compounded combined bevacizumab and triamcinolone. JAMA Ophthalmol 2013;131:864-849.
  46. Goldberg RA, Flynn HW Jr, Miller D, Gonzalez S, Isom RF: Streptococcus endophthalmitis outbreak after intravitreal injection of bevacizumab: one-year outcomes and investigative results. Ophthalmology 2013;120:1448-1453.
  47. Scott IU, Flynn HW Jr: Reducing the risk of endophthalmitis following intravitreal injections. Retina 2007;27:10-12.
  48. Falavarjani KG, Modarres M, Hashemi M, et al: Incidence of acute endophthalmitis after intravitreal bevacizumab injection in a single clinical center. Retina 2013;33:971-974.
  49. Cheung CS, Wong AW, Lui A, et al: Incidence of endophthalmitis and use of antibiotic prophylaxis after intravitreal injections. Ophthalmology 2012;119:1609-1614.
  50. Bhavsar AR, Stockdale CR, Ferris FL, et al: Update on risk of endophthalmitis after intravitreal drug injections and potential impact of elimination of topical antibiotics. Arch Ophthalmol 2012;130:809-810.
  51. Wen JC, McCannel CA, Mochon AB, Garner OB: Bacterial dispersal associated with speech in the setting of intravitreous injections. Arch Ophthalmol 2011;129:1551-1554.
  52. Doshi RR, Leng T, Fung AE: Reducing oral flora contamination of intravitreal injections with face mask or silence. Retina 2012;32:473-476.
  53. Bannerman TL, Rhoden DL, McAllister M, et al: The source of coagulase-negative staphylococci in the Endophthlamitis Vitrectomy Study: a comparison of eyelid and intraocular isolates using pulsed-field gel electrophoresis. Arch Ophthalmol 1997;115:357-361.
  54. Endophthalmitis Vitrectomy Study Group: Results of the Endophthalmitis Vitrectomy Study: a randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis. Arch Ophthalmol 1995;113:1479-1496.
  55. Clark WL, Kaiser PK, Flynn HW Jr, et al: Treatment strategies and visual acuity outcomes in chronic postoperative Propionibacterium acnes endophthalmitis. Ophthalmology 1999;106:1665-1670.
  56. Chaudhry NA, Flynn HW Jr, Smiddy WE, et al: Xanthomonas maltophilia endophthalmitis after cataract surgery. Arch Ophthalmol 2000;188:572-575.
  57. Scott IU, Lieb DF, Flynn HW Jr, et al: Endophthalmitis caused by Mycobacterium chelonae: selection of antibiotics and outcomes of treatment. Arch Ophthamol 2003;121:573-576.
  58. Vahey JB, Flynn HW Jr: Results in the management of Bacillus endophthalmitis. Ophthalmic Surg 1991;22:681-686.
  59. Scott IU, Matharoo N, Flynn HW Jr, et al: Endophthalmitis caused by Klebsiella species. Am J Ophthalmol 2004;138:662-663.
  60. Miller JJ, Scott IU, Flynn HW Jr, et al: Endophthalmitis caused by Streptococcus pneumoniae. Am J Ophthalmol 2004;138:231-236.
  61. Scott IU, Flynn HW Jr, Feuer W, et al: Endophthalmitis associated with microbial keratitis. Ophthalmology 1996;103:1864-1870.
  62. Alfonso EC, Cantu-Dibildox J, Munir WM, et al: Insurgence of Fusarium keratitis associated with contact lens wear. Arch Ophthalmol 2006;124:941-947.
  63. Chang DC, Grant GB, O'Donnell K, et al: Multistate outbreak of Fusarium keratitis associated with use of a contact lens solution. JAMA 2006;296:953-963.
  64. Iyer SA, Tuli SS, Wagoner RC: Fungal keratitis: emerging trends and treatment outcomes. Eye Contact Lens 2006;32:267-271.
  65. Dursun D, Fernandez V, Miller D, et al: Advanced Fusarium keratitis progressing to endophthalmitis. Cornea 2003;22:300-303.
  66. McCannel CA: Meta-analysis of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents: causative organisms and possible prevention strategies. Retina 2011;31:654-661.
  67. Chen E, Lin MY, Cox J, Brown DM: Endophthalmitis after intravitreal injection: the importance of viridans streptococci. Retina 2011;31:1525-1533.
  68. Donahue SP, Kowalski RP, Jewart BH, et al: Vitreous cultures in suspected endophthalmitis: biopsy or vitrectomy? Ophthalmology 1993;100:452-455.
  69. Raju B, Das T: Hyderabad Endophthalmitis Research Group. Simple and stable technique of vitreous tap. Retina 2004;24:803-805.
  70. Josephberg RG: Endophthalmitis: the latest in current management. Retina 2006;26(suppl 6):S47-S50.
  71. Hilton GF, Josephberg RG, Halperin LS, et al: Office-based sutureless transconjunctival pars plana vitrectomy. Retina 2002;22:725-732.
  72. Eser I, Kapran Z, Altan T, et al: The use of blood culture bottles in endophthalmitis. Retina 2007;27:971-973.
  73. Irvine WD, Flynn HW Jr, Murray TG, et al: Retained lens fragments after phacoemulsification manifesting as marked intraocular inflammation with hypopyon. Am J Ophthalmol 1992;114:610-614.
  74. Mamalis N, Edelhauser HF, Dawson DG, et al: Toxic anterior segment syndrome. J Cataract Refract Surg 2006;32:324-333.
  75. Jehan FS, Mamalis N, Spencer TS, et al: Postoperative sterile endophthalmitis (TASS) associated with the MemoryLens. J Cataract Refract Surg 2000;26:1773-1777.
  76. Werner L, Sher JH, Taylor JR, et al: Toxic anterior segment syndrome and possible association with ointment in the anterior chamber following cataract surgery. J Cataract Refract Surg 2006;32:227-235.
  77. Duffy RE, Brown SE, Caldwell KL, et al: An epidemic of corneal destruction caused by plasma gas sterilization. The Toxic Endothelial Cell Destruction Syndrome Investigative Team. Arch Ophthalmol 2000;188:1167-1176.
  78. Moshfeghi AA, Scott IU, Flynn HW Jr, et al: Pseudohypopyon after intravitreal triamcinolone acetonide injection for cystoid macular edema. Am J Ophthalmol 2004;138:489-492.
  79. Nahas Z, Shienbaum G, Smiddy WE, Flynn HW Jr: Hypopyon and pseudoendophthalmitis 1 month after vitrectomy for retinal detachment with subretinal hemorrhage. Ophthalmic Surg Lasers Imaging Retina 2013;44:281-283.
  80. Schwartz SG, Mieler WF, Holz ER, et al: Intravitreal hemoglobin spherulosis: a rare complication of subretinal hemorrhage. Arch Ophthalmol 2002;120:85-87.
  81. Hahn P, Kim JE, Stinnett S, et al: Aflibercept-related sterile inflammation. Ophthalmology 2013;120:1100-1101.
  82. Yamashiro K, Tsujikawa A, Miyamoto K, et al: Sterile endophthalmitis after intravitreal injection of bevacizumab obtained from a single batch. Retina 2010;30:485-490.
  83. Khan P, Khan L, Mondal P: Cluster endophthalmitis following multiple intravitreal bevacizumab injections from a single use vial. Indian J Opthhalmol 2013, Epub ahead of print.
  84. Entezari M, Ramezani A, Ahmadieh H, Ghasemi H: Batch-related sterile endophthalmitis following intravitreal injection of bevacizumab. Indian J Ophthalmol 2014;62:468-471.
  85. Sharma S, Johnson D, Abouammoh H, Hollands S, Brissette A: Rate of serious adverse effects in a series of bevacizumab and ranibizumab injections. Can J Ophthalmol 2012;47:275-279.
  86. Flynn HW Jr, Scott IU: Legacy of the Endophthalmitis Vitrectomy Study (EVS). Arch Ophthalmol 2008;126:559-561.
  87. Durand M: Microbiologic factors and visual outcome in the Endophthalmitis Vitrectomy Study. Am J Ophthalmol 1997;124:127-130.
  88. Doft DH, Wisniewski SR, Kellsy SF, et al: Diabetes and postoperative endophthalmitis in the Endophthalmitis Vitrectomy Study. Arch Ophthalmol 2001;119:650-656.
  89. Tan CS, Wong HK, Yang FP, et al: Outcome of 23-gauge sutureless transconjunctival vitrectomy for endophthalmitis. Eye 2008;22:150-151.
  90. Townsend J, Pathengay A, Flynn HW Jr, Miller D: Management of endophthalmitis while preserving the uninvolved crystalline lens. Clin Ophthalmol 2012;6:453-457.
  91. Han DP, Wisniewski SR, Wilson LA, et al: Spectrum and susceptibilities of microbiologic isolates in the Endophthalmitis Vitrectomy Study. Am J Ophthalmol 1996;122:1-17.
  92. Khera M, Pathengay A, Jindal A, et al: Vancomycin-resistant Gram-positive bacterial endophthalmitis: epidemiology, treatment options, and outcomes. J Ophthalmic Inflamm Infect 2013;3:46.
  93. Jindal A, Pathengay A, Khera M, et al: Combined ceftazidime and amikacin resistance among Gram-negative isolates in acute-onset postoperative endophthalmitis: prevalence, antimicrobial susceptibilities, and visual acuity outcome. J Ophthalmic Inflamm Infect 2013;3:62.
  94. Bispo PJ, Alfonso EC, Flynn HW, Miller D: Emerging 8-methoxyfluoroquinolone resistance among methicillin-susceptible Staphylococcus epidermidis isolates recovered from patients with endophthalmitis. J Clin Microbiol 2013;51:2959-2963.
  95. Iyer MN, Han DP, Yun HJ, et al: Subconjunctival antibiotics for acute postcataract extraction endophthalmitis: is it necessary? Am J Ophthalmol 2004;137:1120-1121.
  96. Smiddy WE, Smiddy RJ, Ba'Arath B, et al: Subconjunctival antibiotics in the treatment of endophthalmitis managed without vitrectomy. Retina 2005;25:751-758.
  97. Hariprasad SM, Mieler WF, Holz ER: Vitreous and aqueous penetration of orally administered gatifloxacin in humans. Arch Ophthalmol 2004;121:345-350.
  98. Park-Wyllie LY, Juurlink DN, Kopp A, et al: Outpatient gatifloxacin therapy and dysglycemia in older adults. N Engl J Med 2006;354:1352-1361.
  99. Duggirala A, Joseph J, Sharma S, et al: Activity of newer fluoroquinolones against Gram-positive and Gram-negative bacteria isolated from ocular infections: an in vitro comparison. Indian J Ophthalmol 2007;55:15-19.
  100. Das T, Jalali S, Gothwal VK, Sharma S, Naduvilath TJ: Intravitreal dexamethasone in exogenous bacterial endophthalmitis: results of a prospective randomised study. Br J Ophthalmol 1999;83:1050-1055.
  101. Breit SM, Hariprasad SM, Mieler WF, et al: Management of endogenous fungal endophthalmitis with voriconazole and caspofungin. Am J Ophthalmol 2005;139:135-140.
  102. Johnson MW, Doft BH, Kelsey SF, et al: The Endophthalmitis Vitrectomy Study: relationship between clinical presentation and microbiologic spectrum. Ophthalmology 1997;104:261-272.
  103. Das T, Kunimoto DY, Sharma S, et al: Relationship between clinical presentation and visual outcome in postoperative and posttraumatic endophthalmitis in south central India. Indian J Ophthalmol 2005;53:5-16.
  104. Rachitskaya AV, Flynn HW Jr, Fisher YL, Ayres B: Correlation between baseline echographic features of endophthalmitis, microbiologic isolates, and visual outcomes. Clin Ophthalmol 2013;7:779-785.
  105. Sridhar J, Flynn HW Jr, Kuriyan AE, Miller D, Albini T: Endogenous fungal endophthalmitis: risk factors, clinical features, and treatment outcomes in mold and yeast infections. J Ophthalmic Inflamm Infect 2013;3:60.

Article / Publication Details

First-Page Preview
Abstract of Retinal Diseases Amenable to Pharmacotherapy

Published online: October 26, 2015
Cover Date: 2016

Number of Print Pages: 13
Number of Figures: 3
Number of Tables: 6

ISBN: 978-3-318-05564-1 (Print)
eISBN: 978-3-318-05565-8 (Online)

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Article Tools
Article Details

Table of Contents

Article

Recommend This
TOP